Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: SUMAVEL DOSEPRO

« Back to Dashboard

Sumavel Dosepro is a drug marketed by Endo Ventures Ltd and is included in one NDA. It is available from one supplier. There are sixteen patents protecting this drug.

The generic ingredient in SUMAVEL DOSEPRO is sumatriptan succinate. There are twenty-three drug master file entries for this compound. Ten suppliers are listed for this compound. There are two tentative approvals for this compound. Additional details are available on the sumatriptan succinate profile page.

Summary for Tradename: SUMAVEL DOSEPRO

Patents:16
Applicants:1
NDAs:1
Suppliers: see list1

Pharmacology for Tradename: SUMAVEL DOSEPRO

Clinical Trials for: SUMAVEL DOSEPRO

A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month Period
Status: Completed Condition: Migraine With or Without Aura; Migraine Disorders; Migraine, Acute; Migraine Headaches

Bioavailability Study to Compare OPTINOSE SUMATRIPTAN With IMITREX® in Healthy Subjects
Status: Completed Condition: Migraine

An Open-label, Randomized, 3-period Crossover Study to Evaluate Sumatriptan Pharmacokinetics for a TREXIMA™ (Sumatriptan Succinate / Naproxen Sodium) Tablet Followed by IMITREX® (Sumatriptan Succinate)
Status: Completed Condition: Migraine With or Without Aura; Migraine Disorders; Cluster Headache; Migraine

Sumatriptan as Treatment for Post-traumatic Headache
Status: Recruiting Condition: Post-traumatic Headache

Comparison of Treximet & Imitrex as They Affect the Levels of Inflammatory Markers When the Patient is Actively Having a Migraine Headache
Status: Completed Condition: Migraine

Evaluation of Treatment Satisfaction and Preference for Sumavel DosePro in the Treatment of Migraine
Status: Completed Condition: Migraine

Sumatriptan and Naratriptan Pregnancy Registry
Status: Completed Condition: Migraine Disorders

Sumatriptan 4 mg Statdose in the Acute Treatment of Cluster Headache
Status: Recruiting Condition: Episodic Cluster Headache; Chronic Cluster Headache

Bioequivalence Study of Sumatriptan Succinate Tablets 100 mg in Fed Conditions
Status: Completed Condition: Healthy

Study to Evaluate the Safety, Tolerability, and Blood Pressure Effect of an Oral Dose of Sumatriptan Alone and in Combination With MK-0974 (Telcagepant) in Migraine Patients (0974-026)
Status: Completed Condition: Migraine Disorders

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Endo Ventures Ltd
SUMAVEL DOSEPRO
sumatriptan succinate
INJECTABLE;SUBCUTANEOUS022239Jul 15, 2009RXYes5,891,086<disabled>Y<disabled>
Endo Ventures Ltd
SUMAVEL DOSEPRO
sumatriptan succinate
INJECTABLE;SUBCUTANEOUS022239Jul 15, 2009RXYes7,776,007<disabled>Y<disabled>
Endo Ventures Ltd
SUMAVEL DOSEPRO
sumatriptan succinate
INJECTABLE;SUBCUTANEOUS022239Jul 15, 2009RXYes7,901,385<disabled>Y<disabled>
Endo Ventures Ltd
SUMAVEL DOSEPRO
sumatriptan succinate
INJECTABLE;SUBCUTANEOUS022239Jul 15, 2009RXYes6,135,979<disabled>Y<disabled>
Endo Ventures Ltd
SUMAVEL DOSEPRO
sumatriptan succinate
INJECTABLE;SUBCUTANEOUS022239Jul 15, 2009RXYes8,241,243<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc